Q2 EPS Estimates for iTeos Therapeutics Decreased by Wedbush
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Free Report) – Equities research analysts at Wedbush lowered their Q2 2025 EPS estimates for iTeos Therapeutics in a research report issued to clients and investors on Monday, April 28th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.85) per share for the quarter, down from their […]
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Free Report) – Equities research analysts at Wedbush lowered their Q2 2025 EPS estimates for iTeos Therapeutics in a research report issued to clients and investors on Monday, April 28th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.85) per share for the quarter, down from their […]
